Deutsche Bank upgrades Centene stock rating on earnings recovery By Investing.com

Deutsche Bank upgraded Centene to Buy from Hold and raised its price target to $80 from $53, implying 12x its 2028 EPS estimate of $6.70. The call reflects confidence in Centene's earnings recovery beyond 2027, alongside a recent Q1 2026 EPS beat of $3.37 versus $2.23 consensus and multiple other bullish analyst revisions. Shares trade at $59.15, up nearly 70% over six months and near the 52-week high of $62.20.

Analysis

The more important signal here is not the upgrade itself, but the rerating gap between managed care names with visible Medicaid stabilization and those still priced for perpetual margin compression. If the market starts underwriting 2028-style earnings power for the group, the largest multiple expansion should accrue to the names with the cleanest path to normalization, while laggards with uncertain enrollment trajectories get punished via multiple dispersion rather than sector-wide moves.

Centene looks like a classic “fundamentals first, price later” setup: the stock has already done a lot of the work, so the next leg likely depends on whether 2026 guidance and subsequent claims data keep validating margin repair. That makes the trade more about estimate durability than upside surprise; if medical cost trends stay benign for another 2-3 quarters, buy-side models will likely lift outer-year EPS and extend the duration of the rally. The risk is that one adverse utilization or state-rate reset can compress the story quickly because the name is now too close to fair-value consensus to absorb disappointment.

Elevance is the subtle loser from this framing. Conservative enrollment assumptions can help near-term optics, but they also leave room for the market to assume less operating leverage if Medicaid turns out better than feared; that makes ELV a relative short candidate if the sector enters a “less bad-than-expected” reassessment phase. Deutsche Bank’s stance also hints that the market may be underappreciating the second-order effect: as managed care earnings recover, capital allocation can shift from defensive balance-sheet preservation toward buybacks, which tends to widen winners/losers inside the sector over a 6-12 month horizon.

The contrarian view is that the rally may already be discounting a best-case path for CNC, while the bigger opportunity is in pair positioning rather than outright longs. If management commentary starts to sound like a 2027-2028 earnings story instead of a 2026 recovery story, the stock can keep working; if not, the re-rating likely stalls and becomes a useful source of funds for higher-conviction healthcare names.

Key Decisions for Investors

• Long CNC / short ELV as a 3-6 month relative-value pair: own the cleaner margin-recovery narrative versus the name with more muted upside from current expectations; target 8-12% pair alpha if Medicaid data stays constructive.
• If not already long, wait for CNC to retest prior highs before adding; upside from here looks more like 5-8% than a fresh rerating, so favor call spreads over stock for a tighter risk/reward.
• Add to CNC only on confirmation of another quarter of stable medical cost trends; thesis breaks if utilization re-accelerates or state funding assumptions tighten, which would likely hit the stock hardest in the next earnings cycle.
• Use ELV as a hedge against sector optimism: small short or underweight into the next managed-care results window, especially if sell-side estimates start converging higher for CNC and peers.
• For healthcare exposure, prefer a pair structure over a basket long: the dispersion in fundamentals is widening, so alpha should come from stock selection, not beta to the group.